The prediction of tissue-to-plasma water partition coefficients (Kpu) from in vitro and in silico data using the tissue-composition based model (Rodgers & Rowland, J Pharm Sci. 2005, 94(6):1237-48.) is well established. However, distribution of basic drugs, in particular into lysosome-rich lung tissue, tends to be under-predicted by this approach. The aim of this study was to develop an extended mechanistic model for the prediction of Kpu which accounts for lysosomal sequestration and the contribution of different cell types in the tissue of interest. The extended model is based on compound-specific physicochemical properties and tissue composition data to describe drug ionization, distribution into tissue water and drug binding to neutral lipids, neutral phospholipids and acidic phospholipids in tissues, including lysosomes. Physiological data on the types of cells contributing to lung, kidney and liver, their lysosomal content and lysosomal pH were collated from the literature. The predictive power of the extended mechanistic model was evaluated using a dataset of 28 basic drugs (pK a ≥ 7.8, 17 β-blockers, 11 structurally diverse drugs) for which experimentally determined Kpu data in rat tissue have been reported. Accounting for the lysosomal sequestration in the extended mechanistic model improved the accuracy of Kpu predictions in lung compared to the original Rodgers model (56% drugs within 2-fold or 88% within 3-fold of observed values). Reduction in the extent of Kpu under-prediction was also evident in liver and kidney. However, consideration of lysosomal sequestration increased the occurrence of over-predictions, yielding overall comparable model performances for kidney and liver, with 68% and 54% of Kpu values within 2-fold error, respectively. High lysosomal concentration ratios relative to cytosol (> 1000-fold) were predicted for the drugs investigated; the extent differed depending on the lysosomal pH and concentration of acidic phospholipids among cell types. Despite this extensive lysosomal sequestration in the individual cells types, the maximal change in the overall predicted tissue Kpu was < 3-fold for lysosome-rich tissues investigated here. Accounting for the variability in cellular physiological model input parameters, in particular lysosomal pH and fraction of the cellular volume occupied by the lysosomes, only partially explained discrepancies between observed and predicted Kpu data in the lung. Improved understanding of the system properties, e.g., cell/organelle composition is required to support further development of mechanistic equations for the prediction of drug tissue distribution. Application of this revised mechanistic model is recommended for prediction of Kpu in lysosomerich tissue to facilitate the advancement of physiologically-based prediction of volume of distribution and drug exposure in the tissues.
Introduction
Tissue-to-plasma water partition coefficients (Kpu) are important drug-related distribution parameters in physiologically-based pharmacokinetic (PBPK) models (Jones et al., 2015; Galetin, 2014; Zhao et al., 2011; Rostami-Hodjegan et al., 2012) . The experimental determination of Kpu requires in vivo studies under steady-state conditions which are laborious and time-intensive. Therefore, several in silico models for the prediction of Kpu from drug-specific physicochemical properties and tissue composition data have been developed (Poulin and Theil, 2000; Rodgers et al., 2005; Rodgers and Rowland, 2006; Berezhkovskiy, 2004; Jansson et al., 2008 ). An initial model by Poulin and Theil (2000) described tissue distribution based on passive processes and accounted for drug dissolution in tissue water in addition to drug binding to neutral lipids, neutral phospholipids and macromolecules. Subsequently, Rodgers et al. incorporated the contribution of electrostatic interactions of moderate-to-strong bases (pK a > 7) with acidic phospholipids (Rodgers et al., 2005; Yata et al., 1990) ; a separate mechanistic model was developed for the prediction of tissue distribution of acids, very weak bases, neutrals and zwitterions (Rodgers and Rowland, 2006) . In the case of moderate-to-strong bases, only the nonionized drug was assumed to bind to neutral lipids and neutral phospholipids, whereas electrostatic interaction with acidic phospholipids was assumed to be the predominant factor for the lipid binding of cationic drug species (Rodgers et al., 2005) . The Rodgers & Rowland model improved accuracy in Kpu predictions of 28 moderate-to-strong bases across a range of tissues (Rodgers et al., 2005) . Despite improved model performances relative to Poulin et al., under-prediction in Kpu (lung) prevailed and both under-and over-predictions of Kpu (brain) were evident (Rodgers et al., 2005) . The same trend in under-prediction of Kpu (lung) for lipophilic bases was confirmed in a comprehensive analysis of six tissue distribution prediction models applied to a set of 81 acidic, basic, neutral and zwitter-ionic compounds (Graham et al., 2012) .
Disregarding lysosomal sequestration of basic drugs in the Rodgers & Rowland model (Rodgers et al., 2005 ) is one possible explanation for the prevailing under-prediction of Kpu (lung). Lysosomes are acidic organelles found in almost all animal and human cells where they act as the main digestive system (Appelqvist et al., 2013) . They are abundant in lungs, liver, kidney and spleen, and in certain cell types such as macrophages where they may contribute even > 10% to the cellular volume (MacIntyre and Cutler, 1988a; Ufuk et al., 2017) . Extensive accumulation of cationic amphiphilic drugs (CAD) in alveolar macrophages and other cell types has been reported and attributed to large extent to subcellular sequestration of basic drugs in lysosomes (MacIntyre and Cutler, 1988a; Vestal et al., 1980; Antonini and Reasor, 1991; Duvvuri et al., 2004; Daniel et al., 1995; Kazmi et al., 2013; Ufuk et al., 2015) . This 'trapping' phenomenon is attributed to pH differences between the cytosol (pH~7.2) and acidic lysosomes (pH~4.5-5), as protonation in the lysosomal environment shifts the equilibrium of the basic drug towards the ionized species (MacIntyre and Cutler, 1988a; Hallifax and Houston, 2007) . This extensive drug ionization in lysosomes and reduced permeability of ionized drug species across the lysosomal membrane may lead to potentially very high drug concentrations in this organelle relative to the cytosol. In addition to the pH gradient, binding of cationic drugs to phospholipids in lysosomal membrane contributes to this subcellular accumulation (MacIntyre and Cutler, 1988a; Hallifax and Houston, 2007) . Prolonged accumulation of CAD in lysosomes has been associated with increased risk of drug-induced phospholipidosis, an important safety concern for potential drug candidates (Reasor et al., 2006; Choi et al., 2013) . CAD-induced phospholipidosis is characterized by extensive accumulation of phospholipids in cells, formation of lamellar inclusion bodies, drug accumulation in association with increased phospholipids and reversibility after discontinuation of drug treatment (Reasor et al., 2006) . Several mechanisms may be involved in the accumulation of phospholipids including direct or indirect inhibition of lysosomal phospholipases (Reasor et al., 2006) . Potential additional implications of drug accumulation in lysosomes on either drug efficacy, drug resistance and/or drug-drug interactions at the level of lysosomes have all been highlighted (Ufuk et al., 2017; Logan et al., 2012) .
Methodological difficulties, e.g., the fragility of lysosomes during homogenization procedures, potential contamination of lysosomes and diffusion of drug from this organelle during the isolation procedure, have hampered direct measurements of lysosomal drug concentrations and determination of the relative importance of lysosomal sequestration in vitro (MacIntyre and Cutler, 1988a) . Studies often rely on indirect assessment of the extent of lysosomal sequestration by i) using agents to abolish existing pH gradient between cytosol and lysosomes (e.g., ammonium chloride, monensin) (Kazmi et al., 2013; Ufuk et al., 2015; Daniel and Wojcikowski, 1997) or ii) measuring cellular Kpu at low and high drug concentrations, assuming that the saturable component of the cellular uptake at a low drug concentration is attributed to the lysosomal sequestration (Hallifax and Houston, 2007) . Indirect methods neglect the effect of ionic strength and changes in membrane surface potential at higher drug concentrations due to insertion of cationic drugs into lipid bilayers (such as lysosomes), which may all affect drug binding to the membrane (Seelig et al., 1996) .
The aims of this study were to extend the existing Rodgers & Rowland mechanistic model (Rodgers et al., 2005) to account for lysosomal sequestration in the prediction of Kpu for moderateto-strong bases, to investigate the impact of this process on Kpu predictions for lysosome-rich tissues and to assess whether consideration of lysosomal sequestration reduces the under-prediction trends previously observed for basic drugs and Kpu (lung) in particular. Physiological data on different cell types contributing to the overall tissue were collated for lung, kidney and liver, including also lysosomal volume fraction and lysosomal pH in individual cell types. Performances of the original and extended tissue-composition models were evaluated in a comparative manner using a dataset of 28 basic drugs employed for development of the original tissue distribution prediction tool (Rodgers et al., 2005) . The impact of variability in physiological model input parameters collated from the literature on Kpu predictions was considered. The scope and limitations of the extended mechanistic model relative to the original Rodgers model and its application for the prediction of tissue distribution within physiologically-based framework are discussed.
Materials and methods

Derivation of a mechanistic equation for the prediction of drug tissue distribution accounting for lysosomal sequestration
The tissue-to-plasma water partition coefficient, Kpu, is defined as the ratio of the total drug concentration in tissue, C Tissue , Total , and the unbound drug concentration in plasma, Cu P , at steady-state:
For each tissue, C Tissue , Total is obtained by diving the total amount of drug in tissue (A Tissue , Total ) by its volume (V Tissue ). A Tissue , Total can be expressed as the sum of amounts of drug in non-lysosomal compartments (A Non − Lys ) and in lysosomes (A Lys ), as shown in Eq. (2).
Expressing A Lys in terms of lysosomal volume (V Lys = f Lys ⋅ V Tissue ) yields Eq. (3), where f Lys represents volume fraction of tissue occupied by lysosomes:
or expressed in terms of concentrations: Rodgers et al. (2005) have proposed a mechanistic equation for the prediction of the drug concentration in tissue and Kpu for compounds with a basic pK a > 7. Drug ionization and drug dissolution in intracellular and extracellular tissue water, in addition to drug binding to neutral lipids, neutral phospholipids and acidic phospholipids were taken into account. In the study by Rodgers et al., a distinction between the distribution of drug into cytosol and subcellular organelles, i.e., the contribution of lysosomal sequestration was not considered. Drug amounts and drug concentrations in tissue estimated by the original Rodgers model are referred to here as A Tissue , R and C Tissue , R , respectively (Eqs. (5) and (6)): 
where Kpu R represents predicted Kpu values by the original Rodgers model. The terms f EW , f IW , f NL and f NP indicate the fractional tissue volumes of extracellular water, intracellular water (cytosol), neutral lipids and neutral phospholipids, respectively. P is the octanol/water partition coefficient and was used as a surrogate for binding of neutral drugs to neutral lipids, whereas a weighted P was applied to reflect the affinity of neutral drugs to neutral phospholipids. More precisely, a hydrophilic-lipophilic balance of phospholipids similar to a mixture of 30% neutral lipids and 70% water was assumed. Electrostatic interaction of cationic drug with acidic phospholipids was described in terms of the association constant of basic compounds with acidic phospholipids (K a ) along with the concentration of acidic phospholipids in different tissues (| AP − | T ). Based on the assumption that K a measured in red blood cells reflects K a in all other tissues, K a can be estimated from Kpu BC (the blood cell-to-plasma water concentration ratio). Drug ionization and pH partitioning were described according to the pK a and pH differences in extracellular water (pH EW ), plasma (pH P , pH P ≈ pH EW ) and intracellular water (cytosol, pH IW ). For further details about the model, the reader is referred to the literature (Rodgers et al., 2005) 
or in terms of drug concentrations:
Provided that C Lys ≫ C Tissue , R , which is true for moderate-to-strongbases accumulating in the acidic lysosomal environment, Eq. (8) simplifies to:
Substitution of Eq. (9) into Eq. (1) yields:
where Kpu R * refers to the revised predicted tissue-to-plasma water partition coefficients that accounts for drug distribution into lysosomes. Lysosome-to-intracellular water partition coefficient (Kpu Lys ) is introduced in order to extend the original Rodgers model by a term reflecting lysosomal sequestration; it is defined as the ratio of the total lysosomal drug concentration (C Lys ) and the unbound concentration in the cytosol (Cu IW ) at steady state:
Model assumptions adapted from the original Rodgers model and applied to the lysosomes are described below. Drug distribution between lysosome and cytosol is described in terms of drug ionization as well as drug dissolution in lysosomal and cytosolic intracellular water. In addition, drug binding to lysosomal lipids, i.e., neutral lipids, neutral phospholipids and acidic phospholipids, is considered. P is used as a surrogate for the binding of neutral drugs to neutral lipids and a weighted P (corresponding to the suggested hydrophilic-lipophilic balance of neutral phospholipids) is applied to reflect the affinity of neutral drugs to neutral phospholipids. Only the nonionized drug binds to neutral lipids and neutral phospholipids within the lysosome, whereas electrostatic interactions with acidic, lysosomal phospholipids govern the binding of cationic drug species. Only the nonionized species is assumed to cross the lysosomal membrane by passive diffusion, and equilibrium is assumed between the unbound nonionized species in the aqueous phase on each side of the lysosomal membrane. Drug ionization and pH partitioning are determined by the pK a of the drug and pH differences between cytosol containing intracellular water (pH IW ) and lysosomes (pH Lys ).
Relative water (f IW ) and lipid volume fractions (f NL , f NP ) as well as the concentration of residual tissue components (| AP − | REM ) in the lysosome were assumed to be equal tof IW , f NL , f NP and | AP − | REM in nonlysosomal compartments of tissue (plasma and other membranes). Given the dominant electrostatic binding of moderate-to-strong bases to acidic phospholipids, | AP − | REM was taken to be the total acidic phospholipid concentration (as in Rodgers et al.) . Since lysosomes do not contain an extraorganelle compartment, the f EW was set to 0. Accordingly, Kpu Lys is given by: (12) Due to the acidic environment of lysosomal water, more pronounced pH differences between lysosome and cytosol (as compared to pH differences between cytosol and plasma, Eq. (5) (Fig. S1 ).
Tissue-specific input parameters
Values for pH P (pH P = 7.4) and pH IW (pH IW = 7.0) as well as tissue-specific values for f EW , f IW , f NL , f NP and |AP − | T in rat lung, liver and kidney were taken from (Rodgers et al., 2005) . The composition of the lysosomal membranes was assumed to be the same as in non-lysosomal compartments of the cell (plasma and membranes of other organelles). In addition, a critical literature review was conducted to collate physiological data for f Cell Type , f Lys and pH Lys in the tissues of interest, as summarized in Table 1 .
In the case of lung tissue, cells with lysosomal origin (alveolar macrophages, type II cells) were considered separately from other residual cells (type I cells, interstitial cells, interstitial matrix, endothelial cells) (Corrin et al., 1969) . Measured data for the lysosomal contribution to the cellular volume has been reported in rat alveolar macrophages (3.7-13.9%, average f Lys(AM) = 7.8% (Ufuk et al., 2017) , whereas only enzymatic studies of the acidic phosphatase activity (indirect marker for f Lys ) were available for type II cells (Corrin et al., 1969; Yayoi et al., 2001; Corrin and Clark, 1968) . Based on the activity of the lysosomal marker enzyme in type II cells relative to alveolar macrophages (Corrin et al., 1969) , a lysosomal volume fraction (f Lys(Type II ) ) of 3% was assumed for the type II cells. With respect to the residual cells, f Lys(Res . Cells) was set to 1% based on the consideration that a certain level of lysosomes in most cells is necessary for maintaining the digestive functions of a cell. Experimental data for lysosomal pH values were available for alveolar macrophages (pH Lys(AM) = 4.75 (mouse; data in rat not available) (Ohkuma and Poole, 1978) ), and for type II cells (pH Lys(Type II) = 5.1 (rat lamellar bodies), (Miklavc et al., 2014) ), but not for residual cells. Therefore, the same lysosomal pH as in type II cells was assumed for residual cells.
Kidney tissue is extremely heterogeneous and data on lysosomal fractions in different kidney cells comprising various morphological units were limited; most data found on f Lys(Kidney ) in different cell types were reported as a sum of primary and secondary lysosomes, including hetero-and autophagosomes (Pfaller, 1982) which all have different properties (e.g., higher intra-vesicular pH) compared to primary lysosomes. The confidence in such f Lys(Kidney ) data was minimal and therefore the mean value of the lysosomal volume fraction in total lung (1.28%) and liver (1.12%) was applied, resulting in the f Lys(Kidney ) of 1.2% (Supplementary Material, Section S2). For the purpose of this analysis, it was assumed that different cell types in the kidney show no difference in the lysosomal volume fraction. Due to the lack of experimentally determined lysosomal pH data in rat kidney, the average value (pH Lys(Kidney ) = 5.1) measured in different kidney-derived cell systems was used (e.g. MDCK cells (Shibata et al., 1983) , cultured human proximal tubular cells (Regec et al., 1989) , for all references see Table 1 ). For consistency, only lysosomal pH values measured with the well-established FITC-Dextran method (Ohkuma and Poole, 1978) were included.
With respect to physiological input data for liver, only liver parenchym (84.1% of total liver) was considered for the calculation of Kpu Lys , whereas intercellular spaces (Disse space, sinusoidal lumen, biliary canaliculi) were not taken into account (Blouin et al., 1977) . Hence, predicted Kpu Lys values were weighted by a factor of 0.841 (Supplementary Material, Section S2). Experimental data for lysosomal Table 1 .
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European Journal of Pharmaceutical Sciences 109 (2017) [419] [420] [421] [422] [423] [424] [425] [426] [427] [428] [429] [430] pH values in rat hepatocytes (pH Lys(Hep ) = 4.72) and rat Kupffer cells (pH Lys(Kupffer ) = 4.94) as well as lysosomal volume fractions in liver cells were obtained from literature (corresponding references listed in Table 1 ). Since no measured pH Lys values in endothelial and fat-storing cells were available, a value of pH Lys = 5.1 was assumed for these cells.
Only lysosomal pH values measured in intact cells were included since pH Lys data obtained in isolated lysosomes tend to overestimate the lysosomal pH (data not shown).
Selection of the dataset and compound-specific input parameters
The measurement of Kpu requires extensive in vivo studies with tissue collection and published data for experimentally determined Kpu in different tissues are sparse. Rodgers et al. have collated experimental Kpu data in lung, kidney, liver and other tissues from 11 studies, along with K a data required for application of the model (Rodgers et al., 2005) . To validate the extended mechanistic model and to facilitate comparative evaluation with the original Rodgers model, we have used the same set of 28 basic compounds (pK a > 7) previously published by Rodgers et al. It is worth noting that Graham et al. (2012) have compared different Kpu prediction models using a 81 compound dataset which contained 8 additional moderate-to-strong bases (pK a ≥ 7). However, none of these additional 8 compounds had Kpu measurements in all of the three tissues investigated in our study (liver, lung, kidney) which made comparisons of model accuracies across different tissues difficult.
Compound-specific input parameters, i.e., measured logP and pK a data, were taken from Rodgers et al. (2005) , Table 2 . For inaperisone, only predicted logP and pK a values were available and were taken as reported. K a values were derived from reported Kpu BC data and additional input parameters (pH BC , f IW, BC , f NL, BC , f NP, BC , AP BC − ) specific to red blood cells as described previously (Rodgers et al., 2005) . Where negative K a values were obtained (phencyclidine and nicotine), the electrostatic interaction of these drugs with acidic phospholipids was assumed to be negligible and K a was set to zero.
Data analysis
The original (Eq. (6)) and extended (Eq. (16)) mechanistic models were used to predict Kpu R and Kpu R * values, respectively for the set of 28 drugs in lysosome-rich tissues in rat, i.e., lung, liver and kidney. Model performance was assessed using a two-fold error margin as criterion; for consistency with previous analyses of Kpu predictions (Poulin and Theil, 2000; Rodgers et al., 2005) , percentage of under-and over-predictions within 3-fold was also assessed. In addition, the coefficient of determination (r 2 , squared Pearson correlation coefficient), as derived from linear regression between observed and predicted Kpu data, was calculated. Absolute deviations between observed and predicted data were calculated in terms of the geometric mean-fold error:
where PRED i and OBS i refer to the predicted and observed Kpu value for the ith compound, respectively, and where n is the total number of observations.
The impact of lysosomal sequestration on accumulation of basic drugs in lungs, liver and kidney was assessed by calculating the ratio between Kpu R and Kpu R * , thus providing a fold-change in predicted tissue distribution by accounting for this process. In the sensitivity analysis, fold changes in Kpu R * were calculated from the ratio of Kpu R * derived using the lowest and highest reported physiological f Lys(AM) estimate (3.7% and 13.9%, respectively). An analogous approach was applied to assess the impact of variability in f Lys(Type II ) and pH Lys . Since experimental data for f Lys(TypeII) and pH Lys(TypeII) were missing, a range of f Lys(TypeII) = 3-6% and pH Lys(TypeII) = 4.7-5.4 was assumed. The applied range for pH Lys(AM) (4.69-4.81) represents the standard deviation of the experimentally determined mean value for this parameter (Ohkuma and Poole, 1978) . In addition, sensitivity analyses was performed to investigate the impact of individual physicochemical parameter on the predicted lung Kpu R * by using the same logP and varying pK a (pK a = 7-11), or vice versa, the same pK a and varying logP (logP = 1-5), as detailed in the Supplementary Material Section 3. (Crapo et al., 1983) . Air and capillary volume was not considered. b Volume fraction of different cell types reported for Sprague-Dawley rat (Blouin et al., 1977) . Intercellular spaces (15.9% of total liver volume) were not considered. c Mean value of lysosomal volume fraction in rat collated from literature as reported in (Ufuk et al., 2015) . d Lysosomal volume fraction in total rat kidney, derived from the sum of absolute volumes for lysosomes in cortex, outer and inner stripe of the outer medulla and inner medulla (Pfaller, 1982) . The fractional volume of lysosomes was obtained by relating the total volume of lysosomes in kidney (34 μL) to the total volume of a standardized kidney (1320 μL). e Values taken as reported in (Blouin et al., 1977) . f Value measured in mouse alveolar macrophages (Ohkuma and Poole, 1978) . g Lysosomal pH measured in lamellar bodies of type II cells in rat (Miklavc et al., 2014) . h Mean value from (Regec et al., 1989; Gekle et al., 1995; Geisow et al., 1981; Ouar et al., 2003; Ling et al., 1996; Golabek et al., 2000; Haggie and Verkman, 2009; Shibata et al., 1983) . Lysosomal pH was measured in intact cells of different cell types and in different species. i Mean value of lysosomal pH in intact rat hepatocytes (MacIntyre and Cutler, 1988b; Myers et al., 1991; Myers et al., 1995; Kharbanda et al., 1997; Tietz et al., 1990) . j Measured in rat Kupffer cells as reported in (Schreiber et al., 1996) . k Values taken as reported by (Rodgers et al., 2005) . Table 2 Physicochemical properties and additional compound-specific input parameters used for the prediction of Kpu in rat lung (n = 25), kidney (n = 28) and liver (n = 26 Mean values predicted using the online packages KOWWIN (erc.syrres.com), Interactive Analysis (LogP.com) and SPARC (ibmlc2.chem.uga.edu/sparc), as stated in Rodgers et al. (2005) .
b
Blood cell-to-plasma water concentration ratio, as stated in Rodgers et al. (2005 2.21-2.70 (phencyclidine: 1.13).
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3. Results
Characterization of the dataset
The 28 compound dataset used for model validation comprised of 17 β-blockers and 11 additional, structurally diverse basic drugs (pK a = 7.8-10.0) of intermediate to high lipophilicity (logP = 0.88-4.96). Key physicochemical properties (pK a , logP) for all drugs in the dataset are listed in Table 2 , along with estimated Kpu BC and K a data used as model input parameters. The dataset covered a broad range of experimental Kpu values (Kpu (lung) = 2.5-1426, Kpu (kidney) = 7-364, Kpu (liver) = 3-327) with the highest extent of drug tissue distribution observed in lung for R-propranolol.
The prediction of drug distribution into lung
Lung tissue is comprised of various different cell types of which alveolar macrophages (f AM = 4.1% of lung tissue) contain the highest lysosomal volume fraction (average f Lys(AM) = 7.8% (Ufuk et al., 2017) ). Similar to alveolar macrophages, type II cells are of lysosomal origin, but with lower contribution of lysosomes to the cellular volume compared to alveolar macrophages (Corrin et al., 1969 Table S3 ). The only exception was phencyclidine, for which only a minor change in predicted Kpu (≤ 8%) was observed with incorporation of the lysosomal sequestration ( Table 2 ). The increase in predicted lung Kpu values was reflected in the reduced percentage of under-predictions (using 2-fold error margin) from 60% (original model) to 32% (model based on AM and residual cells) and to 28% (model based on AM, type II cells and residual cells).
The following drugs remained under-predicted even with the extended model (phencyclidine, S-propranolol, verapamil, S-betaxolol, R-betaxolol, biperiden) with their predicted lung Kpu values representing 31-43% of the observed (phencyclidine being the most pronounced outlier). In the case of imipramine and S-oxprenolol, under-prediction was less pronounced and the predicted Kpu values were on the borderline of the 2-fold error. The most pronounced under-prediction was evident for compounds with the highest measured tissue accumulation (Kpu > 333, Table 2 ), whereas drugs showing low accumulation in the lung tissue were generally predicted well, with the exception of phencyclidine. Lidocaine Kpu (lung) was over-predicted (10-fold), consistent with the original Rodgers model. Use of the extended mechanistic model resulted in the slight over-prediction of Kpu (lung) in the case of S-acebutolol and inaperisone, in contrast to the original model. Application of the extended model resulted in an improved overall prediction accuracy (GMFE < 1.9) compared to the original model (GMFE = 2.653). The consideration of type II cells in addition to alveolar macrophages and residual cells did not yield a significant improvement of the overall model performance (Table 3) ; hence, all the Kpu (lung) results above are based on the extended model based on AM and residual cells.
The prediction of drug distribution into kidney
Comparison of experimental and predicted Kpu in kidney using the original and extended Rodgers model, are shown in Fig. 3B , along with corresponding correlation statistics (Table 3) . Despite the complexity of kidney tissue, the extended mechanistic model assumed equal contribution of lysosomes to the cellular volumes of different cell types and f Lys(Kidney ) was set to 1.2%.
A linear relationship between experimental and predicted Kpu R and Kpu R * was evident, yielding an r 2 of 0.67-0.68. Similar to the lung, consideration of lysosomal sequestration in the model resulted in the overall increase in predicted Kpu values (1.61-1.95 fold, with the exception of phencyclidine) and reduced extent of under-predictions (from 21% to 7% using 2-fold error or 4% when 3-fold error was considered). Compounds which were under-predicted by the extended model were S-acebutolol (42% of the observed Kpu) and nicotine (13% of the observed). However, the extent of over-predictions increased (25% of the dataset relative to 11% in the case of the original Rodgers model), with S-carvedilol (3.7-fold), R-propranolol (4-fold) and R- Table 3 Comparison of the accuracy of Kpu predictions in rat lung (n = 25), kidney (n = 28) and liver (n = 26) using the original and the extended Rodgers model. Statistics are given based on the two-fold and three-fold (in brackets) error margin. Number of drugs under-predicted 15 (9) 8 (2) 7 (1) 6 (3) 2 (1) 7 (2) 0 (0) 0 (0) Number of drugs over-predicted 1 (1) 3 (1) 4 (1) 3 (1) 7 (3) 4 (1) 12 (7) 12 (11) % of drugs under-predicted 60 (36) 32 (8) 28 (4) 21 (11) 7 (4) 27 (8) 0 (0) 0 (0) % of drugs over-predicted 4 (4) 12 (4) 16 (4) 11 (4) 25 (11) 15 (4) 46 (27) 46 (42) % of drugs within 2-fold (and 3-fold) 36 (60) 56 (88) 56 (92) 68 (86) 68 (86) 58 (88) carvedilol (5.6-fold) being the most pronounced outliers. Apart from lidocaine and S-acebutolol, there was no overlap in drugs being over-or under-predicted in lung and kidney tissue. Application of the extended Rodgers model slightly decreased the overall model performance (GMFE of 1.73 vs. 1.91); however, the total number of over-and underpredictions remained unchanged (32%).
The prediction of drug distribution into liver
Liver is considered a lysosome-rich tissue, mainly due to the presence of Kupffer cells. Based on the analysis of collated literature data, these cells contain the highest lysosomal volume fraction among all liver parenchymal cell types (f Lys(Kupffer) = 13.6%), followed by endothelial cells (f Lys(Endoth . Cells) = 6.86%). This is in contrast to hepatocytes (f Lys(Hep) = 0.82%) and fat-storing cells (f Lys(Fat − Storing) = 0.23%; details are shown in Table 1 and Fig. S1B in the Supplementary Material. Despite their abundance of lysosomes, Kupffer and endothelial cells constitute only approximately 5% of total liver parenchym, whereas the largest proportion of liver is composed of hepatocytes (77.8% of total liver parenchym and 84.1% of total liver) (Blouin et al., 1977) . Therefore, the extended mechanistic distribution model was evaluated following two approaches, namely i) applying a complex model with all abovementioned cell types (Kupffer, endothelial, fatstoring cells and hepatocytes) and ii) assuming a simplified model in which liver parenchym was considered to be composed of hepatocytes only with f Lys(Hep) = f Lys(Parenchym) = 0.82%. Fig. 3C shows the comparison of experimental and predicted Kpu R and Kpu R * data in liver using the original and the extended Rodgers model (hepatocytes-only model). As seen in the case of kidney, the consideration of lysosomal sequestration reduced the extent of underprediction, and increased the number of over-predicted Kpu values compared to the original analysis. A drug-dependent increase in predicted Kpu was observed when lysosomal sequestration was considered in the predictive model, with a fold increase ranging from 1.94-2.31 (model based solely on hepatocytes) and 2.21-2.7 (model based on all cell types; phencyclidine was exception in both cases with a maximal 10% increase in predicted liver Kpu). Consideration of either hepatocytes alone or all cell types in the extended mechanistic model resulted in no under-predictions of liver Kpu in contrast to 27% in the original analysis. However, pronounced over-prediction of liver Kpu was evident with the extended model (46% outside 2-fold); this trend was apparent regardless of the cell types considered in the liver model. For certain drugs, the fold over-prediction in liver Kpu was comparable to kidney (R-carvedilol -3.7, R-propranolol -4.7, S-carvedilol -2.4), whereas in some cases the extent of over-prediction was more pronounced relative to either kidney or lung (e.g., pentazocine -26-fold). Lidocaine Kpu was over-predicted for all tissues investigated. Increased number of overpredictions reduced predictive ability of the extended model when comparing performance using 3-fold limits (88% vs. 58% for the original and extended Rodgers model with all cell types, respectively). This was also reflected in the GMFE values ( Table 2) . Consideration of different cell types in the extended model for liver resulted in marginal differences in the total percentage of drugs with liver Kpu predicted within the 2-fold (54-58%).
The prediction of drug distribution into lung -sensitivity analysis
All model predictions of Kpu R * in lung shown so far were based on the average values for the cellular physiological input parameters (f lys and pH lys ), as summarized in Table 1 . In order to assess the impact of parameter variability on Kpu R * predictions, a sensitivity analysis was performed by changing one parameter at a time according to the reported physiological range (Table 4 ). The fraction of cells was kept constant (f AM = 4.1%, f Type II = 8.3% and f Res . Cells = 87.6%) and no shift in the lysosomal pH in presence of drug was assumed.
In the first instance, the sensitivity of Kpu R * to f Lys in alveolar macrophages was investigated using five representative drugs selected from the 28-compound dataset. Rationale for their selection was either the occurrence of under-prediction (S-propranolol, imipramine, biperiden, S-oxprenolol) or over-prediction (lidocaine) by the original Rodgers & Rowland model. Three drugs had the same pK a (9.5) but covered a range of lipophilicity (logP = 2.18-4.8), whereas the remaining two drugs differed in both their pK a and logP (biperiden: pK a = 8.8, logP = 4.25; lidocaine: pK a = 8; logP = 2.44). Fig. 4A shows experimental versus predicted Kpu R and Kpu R * data for the five model drugs; the extended Rodgers model was parameterized with a range of f Lys(AM) (3.7-13.9%, increments of 0.1%); changes in predicted Kpu R * as a function of f Lys(AM) are shown in Fig. 4B .
The maximum 1.33-fold change in predicted Kpu R * was observed over the range in f Lys(AM) = 3.7-13.9% regardless of differences in logP and pK a of the five drugs. Increase in the f Lys(AM) resolved the underprediction trend for all of the selected drugs with the exception of propranolol-S. In order to investigate the impact of f Lys(AM) on Kpu R * for a more diverse set of compounds, the sensitivity analysis was performed for the entire 28-compound dataset. Predicted Kpu R * values for the individual drugs and for settings of f Lys(AM) = 0%, 3.7% and 13.9% are shown in the Supplementary Material (Supplementary Material Table S4 ), along with comparisons of model performances (Supplementary Material  Table S5 ). The analysis showed a 1.26 to 1.34-fold increase in predicted Kpu R * across the physiological f Lys(AM) range (3.7-13.9%); as previously observed, the effect on predicted phencyclidine lung Kpu was minimal (3%). The maximum fold-difference only marginally increased to 1.53 when comparing Kpu R * predictions based on f Lys(AM) = 13.9% and 0%
(assuming no lysosomal contribution in these cells).
Further analysis of the relationship between fold-changes in predicted Kpu R * values and physicochemical properties of the 28-compound dataset showed the following trends (Fig. S3 , Supplementary Material): the absolute changes in predicted Kpu across f Lys(AM) range (3.7-13.9%) increased with increasing logP and increasing experimental Kpu, whereas no clear trend was evident for pK a based on the current dataset. However, relative changes in predicted Kpu R * (i.e. foldchanges) using a range in f Lys(AM) was comparable for all drugs, independent of their logP, pK a or experimental Kpu. Sensitivity analyses was also performed by assessing the impact of individual physicochemical parameters on the predicted lung Kpu R * (pK a = 7-11 and logP = 1-7). Drugs with a basic pK a ≥~8 showed a plateau with almost constant fold-changes in predicted lung Kpu R * over a wide logP range (details are in the Supplementary Material, Fig. S4 ). The impact of the remaining parameters (f Lys(TypeII) , pH Lys(AM) and pH Lys(TypeII) ) on predicted lung Kpu R * values for 28 compounds are shown in the Supplementary Material Table S4 , with summary statistics in Table 4 . Overall, predicted Kpu R * values increased with an increase in the lysosomal volume fraction and a decrease in the lysosomal pH value. Similar to the analysis of the effect of f Lys(AM) , fold changes in predicted lung Kpu R * over a range in these physiological parameters were relatively consistent for the drugs investigated and resulted in maximal 1.14-(f Lys(TypeII) ), 1.26-(pH Lys(AM) ) and 1.89-fold increases (pH Lys(TypeII) ) ( Table 4 ). The analysis showed that fold changes in predicted lung Kpu R * were relatively low when considering the variability of the individual parameters in isolation. A combination of parameters is required in order to explain up to 2.46-fold change in lung Kpu R * evident when comparing the original and the extended Rodgers model.
Discussion
Extended mechanistic model for the prediction of Kpu
In this study, a previously published tissue composition-based model for the prediction of Kpu (Rodgers et al., 2005) was extended to account for the contribution of lysosomal sequestration to drug tissue distribution. Analogous to the original model, drug ionization, drug distribution in tissue water and drug binding to neutral lipids, neutral phospholipids and acidic phospholipids were taken into account. In addition, drug binding to lysosomal lipids and pH differences between lysosome and cytosol were incorporated in the model. The extended mechanistic model also considered differences in cytosolic and lysosomal pH, lysosomal volume fractions and cell volume fractions among individual tissues/cell types; this was implemented using literature collated and critically assessed cellular physiological parameters. The aim of the work was to evaluate the predictive performance of the extended model for lysosome-rich tissues and tissues associated with under-prediction of Kpu in the previous analyses (lung, liver and kidney). Due to limited availability of experimental Kpu data and to allow direct evaluation against the existing model, the dataset consisted of the same 28 moderate-to-strong bases and physicochemical input Predicted Kpu values were derived from the original (black triangles) and the extended Rodgers model (grey squares) parameterized with a range of lysosomal volume fractions in alveolar macrophages (f lys = 3.7-13.9%, grey lines). The remaining input parameters were kept constant at their average values listed in data (i.e.,pK a , logP, K a (inferred from Kpu BC )), as in Rodgers & Rowland work (Rodgers et al., 2005) .
Model performance and the impact of lysosomal sequestration on predicted Kpu
The extended distribution model predicted extensive accumulation of all 28 drugs in lysosomes, as illustrated by the predicted Kpu Lys > 1000 for 79% of the drugs in the dataset in for example alveolar macrophages. The extent of lysosomal accumulation was less pronounced in hepatocytes, but still prominent (Kpu Lys ranging from 94 to 935 for nicotine and imipramine, respectively, Supplementary Material, Table S2 ), reflecting differences in lysosomal pH gradient and concentration of acidic phospholipids among cells. Despite high predicted accumulation in the lysosomes of individual cell types, maximal predicted increase in tissue Kpu as a result of lysosomal sequestration did not exceed 3-fold for the dataset investigated (1.95-2.7 for kidney and liver, respectively); the fold change varied across tissues and assumptions made on their cellular composition ( Table 2 , Supplementary Material Section 2 and Table S3 ).
These results are not entirely surprising considering that lysosomes account for a relatively minor fraction of the entire tissue volume. For example, despite lysosomal volume fractions of 13.6% in Kupffer cells (liver) and up to 13.9% in alveolar macrophages (lung), the fraction of these lysosome-rich cell types in the individual tissues is generally low (< 5%). In contrast, the largest proportion of liver and lung is composed of hepatocytes and residual cells (type I cells, interstitial cells, interstitial matrix, endothelial cells (Corrin et al., 1969) ), respectively, which are not particularly lysosome-rich (e.g., f Lys(Hep) = 0.82%). The same is true for kidney where limited data indicate that proximal tubule cells contain higher lysosomal volume fractions (Pfaller, 1982; Straus, 1964; Condron et al., 1994) .
Application of the extended mechanistic model resulted in no under-prediction of liver Kpu and significantly reduced the extent of under-prediction in the case of the lung (32%) and the kidney (< 10%). However, increase in over-predictions of Kpu relative to the original Rodgers model was evident across all tissues investigated. Overall, consideration of lysosomal sequestration improved Kpu prediction accuracy for lungs, but resulted in comparable performance for liver and kidney (Table 3 ) relative to the model with no consideration of lysosomal trapping. Since the individual consideration of type II cells in addition to alveolar macrophages and residual cells did not yield a significant improvement in the overall lung Kpu, the extended model based on alveolar macrophages and combined residual cells represents the best compromise between predictive performance and model complexity in the case of lung.
Tissue distribution of basic drugs is driven by a combination of phospholipid binding (plasma and lysosomal membrane) and pH-driven lysosomal sequestration (Ufuk et al., 2017; Hallifax and Houston, 2007; Daniel and Wojcikowski, 1997) . The extent of lysosomal accumulation has been suggested to be more prominent for dibasic compared to monobasic drugs, as illustrated by chloroquine (MacIntyre and Cutler, 1988b) . Both the original and extended mechanistic tissue distribution models consider only the first pK a for Kpu predictions. While this simplification is justified for the majority of compounds in the dataset with only one center of ionization, quinidine and timolol have two basic pK a values and ideally the Kpu prediction model should account for this. Consideration of the highest basic pK a in the current study predicted Kpu R * (lung) for both drugs within 2-fold of the experimental data.
Over-prediction in the case of liver was seen for both drugs and for quinidine in kidney, suggesting other contributing factors rather than consideration of a second pK a to the model performance.
Challenges and future perspectives for the mechanistic prediction of Kpu accounting for lysosomal processes
Whereas lysosomal sequestration is linear at low drug concentrations, the capacity of the lysosomes to accumulate basic drugs is reduced at higher drug concentrations as a result of increasing lysosomal pH. Hence theoretical accumulation ratios in lysosomes suggested for certain drugs (e.g., for quinidine: 160.000, (MacIntyre and Cutler, 1988a) ) are most likely not achieved under in vivo conditions. Neither of the mechanistic distribution models account for these nonlinear effects. Although lysosomal pH values are easily modified in the extended Rodgers model, a dynamic change of pH Lys as a function of drug concentration is not accommodated.
The uncertainty in some physiological input parameters such as pH Lys , f Lys and f Cell Type (for tissues like kidney) is a general challenge, as the accuracy of Kpu predictions critically depends on these values. An extensive literature research has been conducted to collate data for all required cellular input parameters. The composition of lysosomal membranes was not available for all cell types and therefore it was assumed that the fraction of lipids, phospholipids and water is the same as in the cell membrane; however, studies report some differences in mitochondrial membrane and high percentage of sphingolipids and lysophosphoglycerides in lysosomal relative to plasma membrane (Daum, 1985) . Physiological input parameters used in the extended model represent average values from different sources, animal strains and methodologies applied. For a number of parameters (e.g., pH Lys in residual cells in lung), no experimental data were reported and therefore estimates based on studies in other cell types had to be used. Despite these limitations, the sensitivity analysis showed that relatively minor changes in predicted Kpu R * are expected when varying pH Lys andf Lys within the physiologically reported range. The disparities seen between predicted and observed Kpu represent a combination of the uncertainty associated with some cellular parameters/assumptions (e.g., setting f Lys(Kidney ) to 1.2%) and true biological variability in physiological parameters (e.g., lysosomal abundance). It is important to note that tissue composition/phospholipid content and cell phenotype may change under certain conditions (e.g., smoking (Hodge et al., 2007; van der Deen et al., 2007) ) which may result in increased relative importance of lysosomal sequestration for drug tissue distribution and higher inter-individual variability. Significant deviations from average physiological input parameters are also anticipated in the case of druginduced pulmonary phospholipidosis which is associated with excessive accumulation of phospholipids in lysosomes and the formation of multilamellar bodies. However, information about the direct impact of lysosomal phospholipid accumulation in the case of phospholipidosis on tissue distribution is scarce (Zheng et al., 2011) . Extension of the current model to any other tissues (e.g., heart) requires collation of physiological data for that particular tissue together with cell composition data, all of which may be limited. In addition to lysosomes, endosomes and the Golgi complex are acidic organelles (Tycko and Maxfield, 1982; Mellman et al., 1986) ) and accumulation of some basic drugs in mitochondria (basic pH environment) has been reported in the literature, but these organelles were not considered in the proposed model. Lamellar bodies in type II cells have been assumed to be more abundant than lysosomes due to their function in storing pulmonary surfactant (Chintagari et al., 2010) . Potential implications of pulmonary surfactants on the uptake of basic drugs have not been considered in the extended mechanistic model and may explain the remaining cases of under-prediction of Kpu (lung).
The accuracy of physicochemical parameters (logP, pK a ) and inconsistencies between measured and calculated parameters (e.g., verapamil measured logP of 3.79 vs. predicted logP value of 4.80 (KOWWIN, v1.67 ) is a usual caveat when using predictive in silico tools. An additional source of uncertainty relates to the K a parameter derived from logP, pK a and Kpu BC . For highly lipophilic drugs and compounds with low-to-intermediate lipophilicity in combination with low pK a , predicted K a values can become negative, as observed for phencyclidine and nicotine, respectively. For these drugs electrostatic interaction with acidic phospholipids in the cell (including the lysosome) was assumed to be negligible and K a was set to zero. Drug binding to acidic phospholipids in lysosomes is considered to amplify lysosomal drug accumulation driven by pH partitioning (MacIntyre and Cutler, 1988a; Hallifax and Houston, 2007) . Neglecting drug binding to acidic phospholipids in the lysosome leads to an underestimation of Kpu Lys and in turn underestimates the fold changes in predicted Kpu values when comparing the models. This effect has been reflected in lower fold-increase in Kpu and lower lysosomal accumulation ratios seen for phencyclidine and nicotine compared to all other drugs.
Potential impact of transporter mediated uptake/efflux to tissue distribution cannot be excluded entirely for the dataset investigated. Verapamil and quinidine are known P-glycoprotein substrates and predicted Kpu values are expected to be over-estimated by the current mechanistic models. This trend was apparent for both drugs in the case of liver Kpu, but not in the case of lung or kidney ( Table 2 ). Some of the over-or under-prediction of kidney Kpu may be attributed to potential contributing role of renal uptake (e.g., OCT2) and efflux transporters (MATE-2 K). However, no clear trends could be established between the extent of liver and kidney Kpu mis-prediction and limited kinetic in vitro/in vivo data on the relevance of transporters for individual compounds in the dataset (collated data for individual drugs shown in the Supplementary Material Table S6 ). For example, in the case of the most pronounced outlier (carvedilol) only evidence for transporter (OCT2) inhibition was reported (Grube et al., 2011) . Further validation on an extended and structurally more diverse dataset is desirable and highly encouraged, as more experimental Kpu data in lysosome-rich tissue become available.
Conclusions
In summary, the proposed mechanistic model for the prediction of Kpu for moderate-to-strong bases (pK a > 7) accounts for lysosomal sequestration by both pH-driven gradient and binding to acidic phospholipids. In addition, important drug-specific and tissue-specific cellular physiological input parameters (e.g., cell volume fractions, lysosomal volume fractions and lysosomal pH) are considered.
Application of the proposed model reduced significantly the extent of Kpu under-prediction in lysosome-rich tissues (lung in particular). Consideration of lysosomal sequestration resulted in the improved prediction accuracy (lung), whereas predictive performance of the model was comparable to the original Rodgers & Rowland model in the case of liver and kidney, despite an increase in over-predictions for these two tissues. The current analysis highlighted high subcellular accumulation for the drugs investigated which may have significant implications for drug safety and efficacy; however, the extent of the increase in the overall tissue distribution as a result of lysosomal sequestration did not exceed 3-fold. A sensitivity analysis confirmed the importance of lysosomal trapping for drug tissue distribution but highlighted that additional processes such as feedback mechanisms and active uptake may contribute to the remaining discrepancy between predicted and observed Kpu values. To further validate the mechanistic model developed, direct measurements of drug lysosomal concentrations and the extent of drug accumulation are required. The application of the extended mechanistic distribution model is recommended for lysosome-rich tissues to support the advancement of PBPK modeling of volume of distribution and drug tissue exposure.
